RU2007112952A - Способы применения лигандов рецепторов смерти и cd20-антител - Google Patents
Способы применения лигандов рецепторов смерти и cd20-антител Download PDFInfo
- Publication number
- RU2007112952A RU2007112952A RU2007112952/13A RU2007112952A RU2007112952A RU 2007112952 A RU2007112952 A RU 2007112952A RU 2007112952/13 A RU2007112952/13 A RU 2007112952/13A RU 2007112952 A RU2007112952 A RU 2007112952A RU 2007112952 A RU2007112952 A RU 2007112952A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- specified
- death receptor
- receptor
- agonistic
- Prior art date
Links
- 108010049207 Death Domain Receptors Proteins 0.000 title claims 18
- 102000009058 Death Domain Receptors Human genes 0.000 title claims 18
- 239000003446 ligand Substances 0.000 title claims 2
- 238000000034 method Methods 0.000 claims 27
- 230000001270 agonistic effect Effects 0.000 claims 12
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 9
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 6
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 6
- 230000003211 malignant effect Effects 0.000 claims 3
- 230000002195 synergetic effect Effects 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108700012411 TNFSF10 Proteins 0.000 claims 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60783404P | 2004-09-08 | 2004-09-08 | |
| US60/607,834 | 2004-09-08 | ||
| US66655005P | 2005-03-30 | 2005-03-30 | |
| US60/666,550 | 2005-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007112952A true RU2007112952A (ru) | 2008-10-20 |
Family
ID=35788041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007112952/13A RU2007112952A (ru) | 2004-09-08 | 2005-09-07 | Способы применения лигандов рецепторов смерти и cd20-антител |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090175854A1 (enExample) |
| EP (1) | EP1802660A2 (enExample) |
| JP (1) | JP2008512479A (enExample) |
| KR (1) | KR20070050951A (enExample) |
| CN (1) | CN101048428A (enExample) |
| AU (1) | AU2005282397A1 (enExample) |
| BR (1) | BRPI0515604A (enExample) |
| CA (1) | CA2577828A1 (enExample) |
| IL (1) | IL181315A0 (enExample) |
| NO (1) | NO20071789L (enExample) |
| NZ (1) | NZ553171A (enExample) |
| RU (1) | RU2007112952A (enExample) |
| WO (1) | WO2006029275A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| EP1756162A1 (en) | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Receptor coupling agents and therapeutic uses thereof |
| WO2008066854A2 (en) * | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
| US9295736B2 (en) | 2007-09-24 | 2016-03-29 | Bar Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| KR101853702B1 (ko) | 2009-12-07 | 2018-05-03 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 항-종양 항체 치료를 향상시키는 방법 |
| DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69533863T2 (de) * | 1994-02-04 | 2006-02-16 | Bio Merieux | MSRV1 Virus der mit Multipler Sklerose verbunden ist, seine nukleären Bestandteile und Verwendungen |
| KR101004174B1 (ko) * | 1995-06-29 | 2010-12-24 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| ATE362982T1 (de) * | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| NZ337795A (en) * | 1997-03-17 | 2001-06-29 | Human Genome Sciences Inc | Death domain containing receptor 5 and it's use in the treatment of DR5 related disease |
| CA2287085A1 (en) * | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| IL137176A0 (en) * | 1998-01-26 | 2001-07-24 | Genentech Inc | Antibodies to 4dr and uses thereof |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| EP1401476A4 (en) * | 2001-03-14 | 2006-03-08 | Genentech Inc | IGF ANTAGONIST PEPTIDES |
| NZ533164A (en) * | 2001-11-01 | 2008-09-26 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
-
2005
- 2005-09-07 JP JP2007531333A patent/JP2008512479A/ja active Pending
- 2005-09-07 NZ NZ553171A patent/NZ553171A/en not_active IP Right Cessation
- 2005-09-07 KR KR1020077005375A patent/KR20070050951A/ko not_active Withdrawn
- 2005-09-07 RU RU2007112952/13A patent/RU2007112952A/ru not_active Application Discontinuation
- 2005-09-07 CN CNA2005800364755A patent/CN101048428A/zh active Pending
- 2005-09-07 BR BRPI0515604-1A patent/BRPI0515604A/pt not_active IP Right Cessation
- 2005-09-07 AU AU2005282397A patent/AU2005282397A1/en not_active Abandoned
- 2005-09-07 EP EP05795474A patent/EP1802660A2/en not_active Withdrawn
- 2005-09-07 CA CA002577828A patent/CA2577828A1/en not_active Abandoned
- 2005-09-07 WO PCT/US2005/032015 patent/WO2006029275A2/en not_active Ceased
- 2005-09-07 US US11/662,315 patent/US20090175854A1/en not_active Abandoned
-
2006
- 2006-10-03 US US11/542,330 patent/US20070231324A1/en not_active Abandoned
-
2007
- 2007-02-13 IL IL181315A patent/IL181315A0/en unknown
- 2007-04-04 NO NO20071789A patent/NO20071789L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL181315A0 (en) | 2007-07-04 |
| JP2008512479A (ja) | 2008-04-24 |
| BRPI0515604A (pt) | 2008-07-29 |
| WO2006029275A2 (en) | 2006-03-16 |
| CN101048428A (zh) | 2007-10-03 |
| NO20071789L (no) | 2007-06-05 |
| KR20070050951A (ko) | 2007-05-16 |
| US20070231324A1 (en) | 2007-10-04 |
| CA2577828A1 (en) | 2006-03-16 |
| AU2005282397A1 (en) | 2006-03-16 |
| NZ553171A (en) | 2010-03-26 |
| EP1802660A2 (en) | 2007-07-04 |
| WO2006029275A3 (en) | 2006-07-27 |
| US20090175854A1 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007112952A (ru) | Способы применения лигандов рецепторов смерти и cd20-антител | |
| Clynes et al. | Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets | |
| US10633450B2 (en) | Methods for enhancing anti-tumor antibody therapy | |
| Ito et al. | Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model | |
| Ring et al. | Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity | |
| Kohrt et al. | CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies | |
| Pers et al. | BAFF‐modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab‐treated patients with Sjögren's syndrome | |
| Klein | Cytokine-binding proteins: stimulating antagonists | |
| RU2007112929A (ru) | Способы применения лигандов рецептора смерти и антител к cd20 | |
| McEarchern et al. | Preclinical characterization of SGN-70, a humanized antibody directed against CD70 | |
| RU2007148932A (ru) | Гуманизированные анти-cd40-антитела и способы их применения | |
| Menon et al. | Itolizumab–a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis | |
| RU2006105642A (ru) | Способы и композиции для повышения эффективности антител для лечебных целей с использованием соединений, потенциирующих nk-клетки | |
| JP2008513354A5 (enExample) | ||
| Yano et al. | Defucosylated anti–CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sézary syndrome | |
| US20100203010A1 (en) | Modulation of tumor microenvironment | |
| CN106963947A (zh) | Nk细胞调节治疗和用于治疗血液恶性疾病的方法 | |
| RU2011148598A (ru) | Антитела к сеасам1 и способы их использования | |
| Lin et al. | Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade | |
| RU2406730C2 (ru) | Гуманизированное моноклональное анти-cd20-антитело | |
| JP2008512479A5 (enExample) | ||
| Georgakopoulou et al. | Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare | |
| Sirivisoot et al. | Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro | |
| Oki et al. | Does rituximab have a place in treating classic Hodgkin lymphoma? | |
| Arcaini et al. | Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100708 |